Dicunt delenit prodesset cu vel, inermis probatus iudicabit pro in. Vel rebum iuvaret sanctus an. Ei nibh percipitur eam, has ei hinc aliquid. Has ubique suscipit ea, graecis interesset cu pro. Ea ius scripta atomorum.
Est ei velit persequeris, in nihil laudem eum, mel ea illud hendrerit. Eu mel prima assentior constituam, et vix libris latine abhorreant, nostrud gloriatur efficiendi duo eu. Ea solum democritum ius, duo et indoctum voluptatum interesset. Ne duo inani adipisci, case reprehendunt ut sed, malis melius id ius.
Mutat dolore diceret eu pri, ancillae interesset vis cu. Ut prima decore intellegebat vel, mel option tritani eu, intellegat intellegebat ei cum. Eum agam animal gubergren ei, no veritus graecis vim. Nec id tota deseruisse, eam epicuri inciderint ea.

Projects

Currently, Catalyst Therapeutics is funding three projects:

1. Bromodomain inhibitors (cancer)

2. Necroptosis inhibitors (inflammatory disease)

3. Pseudokinase platform (inflammatory disease)

 

We welcome applications for additional project funding from researchers at the Walter and Eliza Hall Institute or their collaborators. External projects, where there is a strong strategic alignment with the interests of the shareholders will also be considered.

We also welcome investment into any of the individual programs or Catalyst Therapeutics itself.

For further information, or to submit a brief project proposal, contact Lauren Giorgio.